ATS 2019 Virtual Final Program

CLINICAL • TRANSLATIONAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION D101 CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD 1:30 p.m. - 3:30 p.m. KBHCCD Room D222-D224 (Level 2) Abstract Summaries 1:30-2:00 Viewing/Discussion 2:00-3:30 Chairing: B.D. Levy, MD, ATSF, Boston, MA F. Holguin, MD, MPH, Aurora, CO L.E. Crotty Alexander, MD, ATSF, San Diego, CA 501 Personalised Dosing of Inhaled Asthma therapy/ G. Greene, E. MacHale, R.W. Costello, Dublin, Ireland, p.A7079 502 Efficacy and Safety of a Fixed Combination Extrafine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI Treatment Compared to Fixed Combination BDP/FF in Patients with Uncontrolled Asthma on Medium Dose ICS/LABA:/ P. Paggiaro, P. Kuna, M. Kots, S. Corre, E. Carzana, A. Vele, G. Georges, S. Petruzzelli, J.C. Virchow, Pisa, Italy, p.A7080 503 The Combination of Indacaterol/Glycopyrronium/Mometasone Furoate Is Superior to High-Dose Salmeterol/Fluticasone Propionate in Improving Lung Function in Patients with Asthma/ H. Watz, J.M. Hohlfeld, D. Singh, J. Beier, V. Scholz, Z. Diamant, J. Liu, S. Hua, P. Pinot, I. Jones, A. Sarkar, H.-C. Tillmann, Grobhansdorf, Germany, p.A7081 504 Influence of Prior Treatment Upon the Efficacy of As-Needed Budesonide/Formoterol in Mild Asthma in the SYGMA 1 and 2 Studies/ E. Bateman, P.M. O’Byrne, J.M. FitzGerald, P.J. Barnes, N. Zhong, V. Alagappan, G. Whelan, R. Lamarca, M. Puu, H.K. Reddel, Cape Town, South Africa, p.A7082 505 A Low Exhaled Nitric Oxide Level Excludes a Short-Term Benefit from Inhaled Corticosteroids in Suspected Asthma/ L. Sutherland, K. Shaw, C. Parrish, T. McKeever, I. Stewart, D. Shaw, T. Harrison, Nottingham, United Kingdom, p.A7083 506 High Failure Rate of Anti-IL-5 Therapies in Prednisone-Dependent Asthma Is Associated with Airway Autoimmune Responses/ M. Mukherjee, J. Cherukat, T. Javkar, H. Al-Hayyan, N. Rezaee, M. Kjarsgaard, K. Radford, N. LaVigne, J. Halbecki, A. Dvorkin-Gheva, P.K. Nair, Hamilton, Canada, p.A7084 507 Multiple Components Contribute to Greater Improvements in Quality of Life with IV Reslizumab in the Most Eosinophilic Asthma Patients Compared with the Overall Patient Population/ J.F. Maspero, L. Hickey, M.C. Garin, Buenos Aires, Argentina, p.A7085 508 Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma/ M. Castro, K.F. Rabe, M. Kraft, J. Corren, I.D. Pavord, C. Katelaris, Y. Tohda, M.S. Rice, Y. Lu, P. Rowe, H.W. Staudinger, N. Amin, B. Akinlade, N.M.H. Graham, A. Teper, St. Louis, MO, p.A7086 509 Benralizumab Reduces Asthma Worsening Episodes/ T. Harrison, A.L. Fuhlbrigge, M. Fagerås, A. Jauhiainen, L.E.J.M. Scheepers, J. Zangrilli, C.A. Da Silva, Nottingham, United Kingdom, p.A7087 510 L-Citrulline as Add-On Therapy to Increase Exhaled Nitric Oxide and Improve Lung Function and Asthma Control in Obese Asthmatics/ F. Holguin, S. Sharma, D.E. Winnica, K. Wasil, V.L. Smith, M.H. Cruse, N. Perez, T.J. Scialla, E. Coleman, H. Grasemann, L.G. Que, Aurora, CO, p.A7088 511 Menopausal Hormone Replacement Therapy and Risk of Asthma/ P. Zhang, J.G. Zein, Cleveland, OH, p.A7089 512 Lipid Mediator-Based Molecular Profiling Identified 5 Distinct Asthma Sub-Phenotypes in the U-BIOPRED Study/ S.-E.K. Dahlen, J. Kolmert, C. Gomez, R. Djukanovic, B.U. Dahlen, P.J. Sterk, B. De Meulder, I.M. Adcock, C. Wheelock, Stockholm, Sweden, p.A7090 513 Evidence for an IL-6 High Asthma Phenotype in Asthma Patients of African Ancestry/ S.R. White, B. Laxman, E.T. Naureckas, D.K. Hogarth, J. Solway, A.I. Sperling, C. Ober, Chicago, IL, p.A7091 514 Peroxidases as Biomarkers of Airway Neutrophilic and Eosinophilic Activation in Asthma/ M.C. Peters, E. Dunican, A.R. Charbit, E.R. Bleecker, M. Castro, A.M. Coverstone, S.C. Erzurum, S.A.A. Comhair, A.T. Hastie, M.W. Johansson, N.N. Jarjour, B.D. Levy, E. Israel, B. Phillips, D.T. Mauger, S.E. Wenzel, M.L. Fajt, J.V. Fahy, San Francisco, CA, p.A7092 515 Specific Antibody Response to Seasonal Influenza Vaccine in Chronic Obstructive Pulmonary Disease (COPD) and Healthy Older People/ N. Snape, A. Jarnicki, L. Irving, G.P. Anderson, J.W. Upham, Brisbane, Australia, p.A7093 516 Post-Hoc Analyses of a Phase 2 and Phase 3 Efficacy Trial of an Unadjuvanted Respiratory Syncytial Virus (RSV) F-Glycoprotein Vaccine in Older Adults in the US: A Consistent Signal of Efficacy Against Hospitalizations for Acute Exacerbation of COPD (AECOP/ V. Shinde, I. Cho, N. Thomas, L. Fries, G. Glenn, Gaithersburg, MD, p.A7094 517 Effects of the Novel Inhaled Phosphodiesterase-4 (PDE4) Inhibitor CHF6001 in Targeting Markers of Inflammation in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/ D. Singh, M. Govoni, K.M. Beeh, B. Colgan, O. Kornmann, B. Leaker, H. Watz, G. Lucci, S. Geraci, E. Calabro Rocco, A. Emirova, M.A. Nandeuil, Manchester, United Kingdom, p.A7095 518 Small Airway Epithelial Responses Associated with Enhanced Female Susceptibility to Smoking-Related Lung Disease/ S. O’Beirne, J. Salit, R.J. Kaner, J.G. Mezey, M.J. Thomas, J. Schymeinsky, K. Quast, S. Visvanathan, J.S. Fine, R.G. Crystal, New York, NY, p.A7096 519 The Impact of GOLD Stage on the Effectiveness of Tiotropium/Olodaterol in Preventing COPD Exacerbations in the DYNAGITO Trial/ J.A. Wedzicha, P.M. Calverley, A. Anzueto, A. de la Hoz, F. Voss, K.F. Rabe, C. Jenkins, London, United Kingdom, p.A7097 ATS 2019 • Dallas, TX WEDNESDAY • MAY 22 381 WEDNESDAY AFTERNOON